

Native Human Cancer Antigen 19-9, High Purity

Catalog No.	CSI14767A	Quantity:	25 KU
	CSI14767C		100 KU

Alternate Names: Tumor Marker 19-9, Carbohydrate Antigen 19-9, CA 19-9

Description: Cancer Antigen 19-9 (CA19-9) is the sialylated form of Lewis antigen^A. It is a tetrasaccharide with the sequence Neu5Ac α 2-3Gal β 1-3[Fuc α 1-4]GlcNAc β . It is a serum tumor marker elevated in blood of patients with carcinoma of the gastro-intestinal tract, primarily used to distinguish pancreatic cancer from pancreatitis. CA 19-9 is not sufficiently specific for use as a cancer screening test; however, the specificity for pancreatic cancer increases with increasing levels (high levels showing a specificity of >97% for tumor presence).

Source: Human metastatic liver carcinoma

Biological Activity: \geq 500 kU/mL (Roche Elecsys EIA)

Formulation: 0.1M PBS buffer, pH 7.4 containing 3% sucrose and 0.05% sodium azide

Purification: Gel filtration and ion exchange chromatography

Purity: Highly purified, very low contamination with other cancer antigens.

Appearance: Clear and colorless

Storage & Stability: Store unopened at -20°C to -80°C for at least 1 year. Upon initial thawing, prepare single-use aliquots (\geq 20 μ l) and store at -20°C to -80°C. **Avoid repeated freeze-thaw cycles.**

Infectious Disease Statement: Donor non-reactive for HIV-1/HCV/HBV by NAT; Syphilis, HBcAg, HBsAg, HCV Ab, HIV -1&2 Ab and RPR by currently approved FDA methods. However, because no test method can offer complete assurance that infectious agents are absent, this material should be handled at Bio-Safety Level 2 (BSL 2) as recommended for potentially infectious human serum or blood specimen in the CCD/NIH manual "Biosafety in Microbiological and Biomedical Laboratories", 2009.

Country of Origin: USA

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.